Phase 3, Randomized, Open-Label, Multicenter Study of ARV-471 (PF-07850327) plus Palbociclib versus Letrozole plus Palbociclib for the Treatment of Participants with Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment for Advanced Disease (VERITAC-3)

Project: Research

Project Details

StatusActive
Effective start/end date20/09/2319/09/25

Keywords

  • Clinical trial
  • C4891002